|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600117830 |
|
最近更新日期: Date of Last Refreshed on: |
2026-01-29 10:10:59 |
|
注册时间: Date of Registration: |
2026-01-29 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
从心理、生理角度分析早泄患者发病的风险因素及可控方法的多中心研究 |
|
Public title: |
A multi-center study examining the risk factors and controllable methods for patients with premature ejaculation, focusing on both psychological and physiological perspectives |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
从心理、生理角度分析早泄患者发病的风险因素及可控方法的多中心研究 |
|
Scientific title: |
A multi-center study examining the risk factors and controllable methods for patients with premature ejaculation, focusing on both psychological and physiological perspectives |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
郭雨鸣 |
研究负责人: |
苏新军 |
|
Applicant: |
Guo Yuming |
Study leader: |
Su Xinjun |
|
申请注册联系人电话: Applicant telephone: |
+86 133 8750 8173 |
研究负责人电话:
Study leader's |
+86 159 0717 6726 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
921807502@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
1919519046@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国湖北省武汉市武昌区东湖路169号 |
研究负责人通讯地址: |
中国湖北省武汉市武昌区东湖路169号 |
|
Applicant address: |
169 Donghu Road, Wuchang District, Wuhan, Hubei, China |
Study leader's address: |
169 Donghu Road, Wuchang District, Wuhan, Hubei, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
武汉大学中南医院 |
||
|
Applicant's institution: |
Zhongnan Hospital of Wuhan University |
||
|
研究负责人所在单位: |
武汉大学中南医院 |
||
|
Affiliation of the Leader: |
Zhongnan Hospital of Wuhan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
临研伦[2021081] |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
武汉大学中南医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Zhongnan Hospital of Wuhan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-03-15 00:00:00 | ||
|
伦理委员会联系人: |
胡梦薇 |
||
|
Contact Name of the ethic committee: |
Mengwei Hu |
||
|
伦理委员会联系地址: |
中国湖北省武汉市武昌区东湖路169号门诊楼11楼 |
||
|
Contact Address of the ethic committee: |
Outpatient building, 11 floor, 169 Donghu Road, Wuchang District, Wuhan, Hubei, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 27 6781 2787 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
武汉大学中南医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Zhongnan Hospital of Wuhan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国湖北省武汉市武昌区东湖路169号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
169 Donghu Road, Wuchang District, Wuhan, Hubei, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中南医院科技创新培养基金项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Zhongnan hospital of wuhan university of science and technology innovation cultivation fund clinical research (industrialization) project |
||||||||||||||||||||||
|
研究疾病: |
早泄 |
||||||||||||||||||||||
|
Target disease: |
Premature ejaculation |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
从性伴侣双方的心理、生理角度分析早泄患者发病的可能风险因素,研究早泄患者的性格类型分类、心率等心理、生理指标的相关性。将为进一步提示早泄的发病机制提供重要的线索,同时将为探寻合理、有效及个体的早泄心理、生理治疗提供重要的依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
Analyze the possible risk factors for premature ejaculation from the psychological and physiological perspectives of both sexual partners, and study the correlation between personality type classification, heart rate, and other psychological and physiological indicators of premature ejaculation patients. This will provide important clues for further elucidating the pathogenesis of premature ejaculation, and also provide important basis for exploring reasonable, effective, and individual psychological and physiological treatments for premature ejaculation. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
选取自泌尿男科的门诊病人,根据主诉、体格检查、辅助检查经临床诊断为早泄的患者,自愿参加并签署知情同意书 1.入组病人为早泄患者 2.患者年龄18-50岁,身体一般情况良好 3.患者有固定的性伴侣,规律性生活半年以上,近1个月内6次及以上性生活;在研究期间保证每周1-2次性生活。 4.原发性早泄诊断 5.外周型早泄诊断:阴茎定量感觉阈值测定或阴茎震动阈值测定 |
||||||||||||||||||||||
|
Inclusion criteria |
Select outpatient patients from urology and urology departments who have been clinically diagnosed with premature ejaculation based on their chief complaint, physical examination, and auxiliary examinations, and voluntarily participate and sign an informed consent form 1.The enrolled patients are premature ejaculation patients 2.The patient is aged 18-50 years old and generally in good physical condition 3.The patient has a fixed sexual partner, has had regular sexual activity for more than six months, and has had six or more sexual activities in the past month; Ensure 1-2 sexual activities per week during the study period. 4.Diagnosis of primary premature ejaculation 5.Diagnosis of peripheral premature ejaculation: quantitative sensation threshold measurement or penile vibration threshold measurement |
||||||||||||||||||||||
|
排除标准: |
1.排除筛选前4周内服用过5羟色胺能活性药物(如氯胺酮等)、SSRIs、TCA类制剂、PDE5i以及试验期间必须服用上述药物者; 2. 排除合并精神疾病、心脑血管疾病、肝肾功能不全、酒精依赖者; 3. 排除勃起功能障碍(勃起功能情况应用IIEF-5评分表评估)者; 4. 已知对研究药物及其辅料成分过敏者; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Exclude those who have taken serotonergic active drugs (such as ketamine), SSRIs, TCA preparations, PDE5i, and those who must take the above drugs during the trial period within the 4 weeks prior to screening; 2.Exclude individuals with comorbidities of mental illness, cardiovascular and cerebrovascular diseases, liver and kidney dysfunction, and alcohol dependence; 3.Exclude individuals with erectile dysfunction (assessed using the IIEF-5 scoring system for erectile function); 4.Individuals known to be allergic to the study drug and its excipient components |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-03-01 00:00:00至 To 2024-05-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-03-20 00:00:00 至 To 2023-04-28 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男性 |
Gender: |
Male |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
项目使用白塔数据EDC进行管理(https://www.onetopdata.com/home)请联系项目负责人获取相关数据查阅权限,数据于2026年6月后公开 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The project is managed using Baita Data EDC (https://www.onetopdata.com/home). Please contact the project leader to obtain relevant data access permissions |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
项目使用白塔数据EDC进行管理(https://www.onetopdata.com/home) 请联系项目负责人获取相关数据查阅权限 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The project is managed using Baita Data EDC (https://www.onetopdata.com/home). Please contact the project leader to obtain relevant data access permissions |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |